Clinical importance of muscle volume in lenvatinib treatment for hepatocellular carcinoma: Analysis adjusted with inverse probability weighting.

ABSTRACT:

Background and aim

This study aimed to elucidate the clinical importance of muscle volume loss (pre-sarcopenia) in patients receiving lenvatinib as treatment for unresectable hepatocellular carcinoma (u-HCC).

Methods

Of 437 u-HCC patients treated with lenvatinib at specific institutions in Japan between March 2018 and May 2020, 151 with available computed tomography imaging data from the time of lenvatinib introduction were enrolled. Pre-sarcopenia was diagnosed based on a previously reported cut-off value calculation formula [psoas muscle area at level of middle of third lumbar vertebra (cm² )/height (m)² ]. Clinical features and prognostic factors for overall survival (OS) with inverse probability weighting were investigated retrospectively for their

SUBMITTER: Hiraoka A 

PROVIDER: S-EPMC8359359 | biostudies-literature | 2021 Jul

REPOSITORIES: biostudies-literature